Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Based on the results of the phase Ib/II study, the investigators hypothesize that combining a RET inhibitor lenvatinib with endocrine therapy letrozole improves objective response and progression-free survival compared to fulvestrant alone in the second line setting in patients who have progressed on first line endocrine therapy incorporating a CDK4/6 inhibitor. Letrozole and fulvestrant are anti-hormonal drugs that have been proven to have activity and are considered standard therapies for hormone receptor positive breast cancer. The purpose of this study is to determine if the combination t

Trial Details

NCT ID
NCT05181033
Phase
PHASE2
Sponsor
National University Hospital, Singapore
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Lenvatinib + Letrozole
  • Fulvestrant
Locations (sample)
  • Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

  • Patients may be included in the study only if patient meet all of the following criteria:
  • Female, age =\>18 years.
  • Histologic or cytologic diagnosis of breast carcinoma.
  • Estrogen receptor positive (defined as =\>1% on immunohistochemical staining)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →